β-defensin 14 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of β-defensin 14, a member of the defensin family of small, cysteine-rich antimicrobial peptides. β-defensin 14 plays an essential role in the innate immune system, contributing to the defense against pathogens such as bacteria, fungi, and viruses by disrupting their cell membranes. This peptide is known for its ability to bind to microbial cell surfaces, leading to membrane destabilization and the destruction of pathogens. Inhibitors of β-defensin 14 aim to block its antimicrobial activity, potentially affecting the peptide's ability to bind to microbial membranes or interact with specific components of the immune response.
The development of β-defensin 14 inhibitors involves a detailed understanding of the peptide's structure, particularly its β-sheet-rich conformation stabilized by disulfide bridges, which is essential for its function in binding to microbial surfaces. These inhibitors are designed to interact with key regions of the peptide, such as its positively charged surface or hydrophobic regions, which are critical for membrane binding and antimicrobial activity. Structural biology techniques, including molecular modeling and X-ray crystallography, are commonly employed to identify these critical regions and to design inhibitors that specifically bind to them, preventing β-defensin 14 from carrying out its membrane-disrupting functions. Achieving high specificity is crucial in this process, as β-defensin 14 shares structural and functional similarities with other members of the defensin family. These inhibitors are valuable tools for studying the detailed mechanisms of host-microbe interactions, shedding light on the complex dynamics of innate immune responses and the role of defensins in protecting against microbial invaders.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylases, potentially reducing RIM-BP3B expression by altering chromatin structure. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor may decrease RIM-BP3B expression by impacting gene methylation patterns. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA and halts RNA polymerase action, potentially reducing RIM-BP3B mRNA synthesis. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, which could lead to decreased transcription of RIM-BP3B. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus inhibits mTOR, which may downregulate RIM-BP3B expression by affecting protein synthesis pathways. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis, potentially decreasing the production of RIM-BP3B. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine can alkalize lysosomes, potentially interfering with the degradation pathways of RIM-BP3B mRNA. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could lead to reduced expression of RIM-BP3B by affecting downstream signals. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A binds to DNA, potentially decreasing RIM-BP3B expression by inhibiting RNA synthesis. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
It inhibits glycolysis, potentially reducing energy for RIM-BP3B expression and other cellular processes. | ||||||